Absci
Absci Corp is an American generative AI drug creation company deploying artificial intelligence and synthetic biology for biologic drug discovery. The company utilizes its Integrated Drug Creation platform to design and engineer novel antibodies and protein therapeutics in silico. Principal revenues are generated through upfront licensing fees, R&D milestone payments, and future royalty sharing with biopharmaceutical partners. Core end markets serve global pharmaceutical corporations, biotechnology developers, and academic research institutions. Absci holds a prominent pioneer position in the biopharmaceutical industry as a technology developer integrating generative AI models with high-throughput wet-lab antibody screening. The company is headquartered in Vancouver, Washington, and its common stock trades on the Nasdaq Global Select Market.
2 of the funds FundTelligence covers report a position in Absci.
- Legal name
- ABSCI CORP
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
- Exposure themes
- Artificial Intelligence, Drug Discovery & Design, Healthcare
Funds holding Absci
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.14 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)